human foreskin fibroblasts hff cell lines (Pasteur Institute)
86
Structured Review
Pasteur Institute
human foreskin fibroblasts hff cell lines
Human Foreskin Fibroblasts Hff Cell Lines, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+foreskin+fibroblasts+cell+line+(hff)/fibroblast+foreskin+human/10__1007_slash_s10876___025___02959___z-36-5-16
Average 86 stars, based on 1 article reviews
Human Foreskin Fibroblasts Hff Cell Lines, supplied by Pasteur Institute, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+foreskin+fibroblasts+cell+line+(hff)/fibroblast+foreskin+human/10__1007_slash_s10876___025___02959___z-36-5-16
Average 86 stars, based on 1 article reviews
human foreskin fibroblasts hff cell lines - by Bioz Stars,
2026-10
86/100 stars
Images
Related Articles
Activity Assay:Article Title: Enhanced antimicrobial effects of carvacrol against methicillin-resistant Staphylococcus aureus strains using niosome formulations. Article Snippet: The ntibiotic profile evaluated included cefoxitin (10 g), vanomycin (10 g), ciprofloxacin (5 g), penicillin (10 g), rythromycin (15 g), trimethoprim (12.5 g), amikacin 15 g), ampicillin (10 g), gentamicin (10 g), amoxicillin 10 g), chloramphenicol (15 g) and clindamycin (10 g). he S. aureus ATCC 25923 strain served as the positive conrol. ntimicrobial activity of carvacrol--niosomes ompared to the free drug easurement of MIC and MBC o evaluate the antibacterial efficacy of the arvacrol--niosome formulation and its free form, the tudy utilized minimum inhibitory concentration (MIC) and I F i PRESS za Mohammadi et al. inimum bactericidal concentration (MBC) procedures. herefore, the MIC assessment, conducted in accorance with CLSI standards, involved a microbroth dilution pproach and was executed in triplicate for precision. oncentrations spanning from 7.8 to 1000 g/ml were used o determine the MIC for the samples. ell culture and cell viability assay he Article Title: Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells. Article Snippet: The Human foreskin fibroblasts (HFF) cell line and Article Title: Green Synthesis and Bioactivity of Aliphatic N-Substituted Glycine Derivatives. Article Snippet: The Article Title: Chitosan -based nanoniosome for potential wound healing applications: Synergy of controlled drug release and antibacterial activity. Article Snippet: This study aims to develop a niosomal platform which can delivery drugs such as tetracycline hydrochloride (TCH) to treat bacterial infections in wounds.. To this end, chitosan (CS) was used to obtain a controlled drug release and at the same time antibacterial activity.. By design of experiments the niosome encapsulated TCH (TCH-Nio) were optimized for their particle size and encapsulation efficiency, followed by analysis of the release profile of TCH and stability of TCH-Nio and TCH-Nio@CS. Formulation:Article Title: Enhanced antimicrobial effects of carvacrol against methicillin-resistant Staphylococcus aureus strains using niosome formulations. Article Snippet: The ntibiotic profile evaluated included cefoxitin (10 g), vanomycin (10 g), ciprofloxacin (5 g), penicillin (10 g), rythromycin (15 g), trimethoprim (12.5 g), amikacin 15 g), ampicillin (10 g), gentamicin (10 g), amoxicillin 10 g), chloramphenicol (15 g) and clindamycin (10 g). he S. aureus ATCC 25923 strain served as the positive conrol. ntimicrobial activity of carvacrol--niosomes ompared to the free drug easurement of MIC and MBC o evaluate the antibacterial efficacy of the arvacrol--niosome formulation and its free form, the tudy utilized minimum inhibitory concentration (MIC) and I F i PRESS za Mohammadi et al. inimum bactericidal concentration (MBC) procedures. herefore, the MIC assessment, conducted in accorance with CLSI standards, involved a microbroth dilution pproach and was executed in triplicate for precision. oncentrations spanning from 7.8 to 1000 g/ml were used o determine the MIC for the samples. ell culture and cell viability assay he Article Title: Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells. Article Snippet: The Human foreskin fibroblasts (HFF) cell line and Article Title: Green Synthesis and Bioactivity of Aliphatic N-Substituted Glycine Derivatives. Article Snippet: The Article Title: Chitosan -based nanoniosome for potential wound healing applications: Synergy of controlled drug release and antibacterial activity. Article Snippet: This study aims to develop a niosomal platform which can delivery drugs such as tetracycline hydrochloride (TCH) to treat bacterial infections in wounds.. To this end, chitosan (CS) was used to obtain a controlled drug release and at the same time antibacterial activity.. By design of experiments the niosome encapsulated TCH (TCH-Nio) were optimized for their particle size and encapsulation efficiency, followed by analysis of the release profile of TCH and stability of TCH-Nio and TCH-Nio@CS. Concentration Assay:Article Title: Enhanced antimicrobial effects of carvacrol against methicillin-resistant Staphylococcus aureus strains using niosome formulations. Article Snippet: The ntibiotic profile evaluated included cefoxitin (10 g), vanomycin (10 g), ciprofloxacin (5 g), penicillin (10 g), rythromycin (15 g), trimethoprim (12.5 g), amikacin 15 g), ampicillin (10 g), gentamicin (10 g), amoxicillin 10 g), chloramphenicol (15 g) and clindamycin (10 g). he S. aureus ATCC 25923 strain served as the positive conrol. ntimicrobial activity of carvacrol--niosomes ompared to the free drug easurement of MIC and MBC o evaluate the antibacterial efficacy of the arvacrol--niosome formulation and its free form, the tudy utilized minimum inhibitory concentration (MIC) and I F i PRESS za Mohammadi et al. inimum bactericidal concentration (MBC) procedures. herefore, the MIC assessment, conducted in accorance with CLSI standards, involved a microbroth dilution pproach and was executed in triplicate for precision. oncentrations spanning from 7.8 to 1000 g/ml were used o determine the MIC for the samples. ell culture and cell viability assay he Article Title: Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells. Article Snippet: The Human foreskin fibroblasts (HFF) cell line and Article Title: Green Synthesis and Bioactivity of Aliphatic N-Substituted Glycine Derivatives. Article Snippet: The Article Title: Chitosan -based nanoniosome for potential wound healing applications: Synergy of controlled drug release and antibacterial activity. Article Snippet: This study aims to develop a niosomal platform which can delivery drugs such as tetracycline hydrochloride (TCH) to treat bacterial infections in wounds.. To this end, chitosan (CS) was used to obtain a controlled drug release and at the same time antibacterial activity.. By design of experiments the niosome encapsulated TCH (TCH-Nio) were optimized for their particle size and encapsulation efficiency, followed by analysis of the release profile of TCH and stability of TCH-Nio and TCH-Nio@CS. Viability Assay:Article Title: Enhanced antimicrobial effects of carvacrol against methicillin-resistant Staphylococcus aureus strains using niosome formulations. Article Snippet: The ntibiotic profile evaluated included cefoxitin (10 g), vanomycin (10 g), ciprofloxacin (5 g), penicillin (10 g), rythromycin (15 g), trimethoprim (12.5 g), amikacin 15 g), ampicillin (10 g), gentamicin (10 g), amoxicillin 10 g), chloramphenicol (15 g) and clindamycin (10 g). he S. aureus ATCC 25923 strain served as the positive conrol. ntimicrobial activity of carvacrol--niosomes ompared to the free drug easurement of MIC and MBC o evaluate the antibacterial efficacy of the arvacrol--niosome formulation and its free form, the tudy utilized minimum inhibitory concentration (MIC) and I F i PRESS za Mohammadi et al. inimum bactericidal concentration (MBC) procedures. herefore, the MIC assessment, conducted in accorance with CLSI standards, involved a microbroth dilution pproach and was executed in triplicate for precision. oncentrations spanning from 7.8 to 1000 g/ml were used o determine the MIC for the samples. ell culture and cell viability assay he Article Title: Bioresponsive gingerol-loaded alginate-coated niosomal nanoparticles for targeting intracellular bacteria and cancer cells. Article Snippet: The Human foreskin fibroblasts (HFF) cell line and Article Title: Green Synthesis and Bioactivity of Aliphatic N-Substituted Glycine Derivatives. Article Snippet: The Article Title: Chitosan -based nanoniosome for potential wound healing applications: Synergy of controlled drug release and antibacterial activity. Article Snippet: This study aims to develop a niosomal platform which can delivery drugs such as tetracycline hydrochloride (TCH) to treat bacterial infections in wounds.. To this end, chitosan (CS) was used to obtain a controlled drug release and at the same time antibacterial activity.. By design of experiments the niosome encapsulated TCH (TCH-Nio) were optimized for their particle size and encapsulation efficiency, followed by analysis of the release profile of TCH and stability of TCH-Nio and TCH-Nio@CS. |
